Overview
Updated 14 Jul 2026
Toby Maher, MD, is Professor of Clinical Medicine, Director of Interstitial Lung Disease at Keck School of Medicine of the University of Southern California (USC). The public record shows 944 publications with 35,184 citations (h-index 96), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Chronic Obstructive Pulmonary Disease (COPD) Research. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 24 companies, 1 NIH-funded awards (2025–2025).
- Most recent indexed publication: 2026 · The European respiratory journal
- Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 109 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 307.
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ipf-summit.com ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Sponsor: Avalyn Pharma Inc.
InvestigatorPhase 2RecruitingNCT06951217 - A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Sponsor: GlaxoSmithKline
InvestigatorPhase 3RecruitingNCT06572384 - Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
Sponsor: Redx Pharma Ltd
InvestigatorPhase 2Active, not recruitingNCT05570058
Industry payments
Updated 14 Jul 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20253 payments$101,816openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim International GmbHProgram year202543 payments$86,964openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202518 payments$26,383openpaymentsdata.cms.gov ↗
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- Pre-clinical development of a small molecule therapeutic for the systemic treatment of idiopathic pulmonary fibrosis
University of Southern California
FY2025$943,301UG3AG097137
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets.
The European respiratory journal
2026 - Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
The European respiratory journal
2026 - Progressive pulmonary fibrosis: the importance of identification and intervention.
European respiratory review
2026
Most-cited worksby citation count (OpenAlex)
- 01Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease1,620 citations2019
- 02
- 03Interstitial Lung Disease in Systemic Sclerosis1,194 citations2008
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1510 San Pablo St. HC1 - Suite 514, Los Angeles, CA 90033
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →keckmedicine.org ↗
Editorial & leadership rolesjournal and society appointments
- Associate Editor
American Journal of Respiratory and Critical Care Medicine (AJRCCM)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →atsjournals.org ↗ - Editorial/International Advisory Board
The Lancet Respiratory Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thelancet.com ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.sc-ctsi.org ↗
Secondary affiliationsappointments beyond the home institution
- Professor
National Heart and Lung Institute, Imperial College London (Fibrosis Research Group, Inflammation, Repair and Development Section)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Medical Advisor / Advisor
NeRRe Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗ - Medical Advisor
Lung Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗
Media & interviewspress, podcasts and appearances
- Medscape InDiscussion podcast
Season 1 Episode 6: "Now Unfolding: The Future of Idiopathic Pulmonary Fibrosis" (with Dr. Jeffrey Swigris)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗ - Rheumatology Advisor podcast: "The Breath-Taking Lungs and Scleroderma"
interview on prevalence of lung involvement in scleroderma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumatologyadvisor.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- LinkedIn
linkedin.com/in/toby-maher
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Toby-Maher
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/toby-maher-00b71530
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by otherswhere others cite or feature them
- Instagram
instagram.com/p/DQpa6OSDZtv
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Apple Podcasts
podcasts.apple.com/us/podcast/toby-maher-md-msc-phd-rethinking-pulmonary-fibrosis/id946943193
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this specialty yet.